Medication Use Before and After Hip Fracture: A Population-Based Cohort and Case-Control Study
Osteoporosis, together with age, is the main risk factor for hip fracture, the incidence of which has also been associated with an increased risk of falling or co-morbidities and related pharmacological treatments.
The aim of this study was to investigate changes in concomitant pharmacological treatments prescribed before and after hip fracture in elderly patients compared with treatments prescribed to a matched cohort of subjects without hospitalisation for fractures.
Data relating to the study population were extracted from a large population-based administrative database of the Italian National Health Authorities. A retrospective analysis was conducted involving female patients (6,431) aged ≥65 years and hospitalised for a hip fracture. The control group comprised age-matched subjects (38,586) not hospitalised for fracture. Changes in drug prescriptions 1 year before and 1 year after hip fracture and differences versus controls were compared.
Prior to the fracture, patients were taking more anti-Parkinson medications, antidepressants, medications for chronic obstructive pulmonary disease (COPD), bisphosphonates and calcium–vitamin D supplements, although the intake of the routinely monitored drug classes was significantly infrequent. Polypharmacy was less frequent in fractured women before fracture than in controls (22 vs. 25 %, respectively; P < 0.001), but it was more frequent (30 %, P < 0.001) post-fracture. The incidence of fracture was associated with a significant increase in the use of a number of drug classes: insulin, NSAIDs or analgesics, gastroprotectants, loop diuretics, β-blockers, antidepressants, antiparkinson drugs, antiepileptics and drugs for COPD.
Our study confirms a strong association between the use of some drugs (antidepressants, antiparkinson drugs, drugs for COPD) and the risk of hip fracture, but drug use is globally less common than in controls. Hip fracture is associated with a significant increase in drug use, suggesting a global deterioration of health conditions.
KeywordsChronic Obstructive Pulmonary Disease Bisphosphonates Raloxifene Teriparatide Loop Diuretic
This study was supported by independent research grants from Amgen Dompe and GlaxoSmithKline. The grant providers had no role in the study design, data collection, statistical analysis, or manuscript preparation and submission.
Conflict of interest
S.A. has received consultancy honoraria from Merck and Amgen, and speaking fees from Amgen, Abiogen, Merck, Eli-Lilly, Pfizer, Novartis and GSK. O.V. has received speaking fees from Merck and Pfizer. L.I. has received speaking fees from Novartis. L.D.E. has received speaking fees from Amgen and Eli-Lilly. D.G. has received speaking fees from Amgen, Abiogen, Merck, Eli-Lilly and Pfizer. All other authors have declared no conflicts of interest.
- 1.Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.PubMedCentralPubMedCrossRefGoogle Scholar
- 52.Vestergaard P, Hermann P, Jensen JE, et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23:1255–65.PubMedCrossRefGoogle Scholar
- 54.Degli Esposti L, Adami S, Iolascon G, et al. Il costo delle fratture da osteoporosi in Italia. Risultati dello studio BLOCK (Bone Loss and Osteoporosis: Cost-of-illness Knowledge). Farmeconomia e Percorsi Terapeutici. 2011;12:89–95.Google Scholar